EN
SINOVAC's Influenza Vaccine (Split Virion), Inactivated (MDCK Cell) Granted Clinical Trial Approval
May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The Phase I clinical research of the vaccine is scheduled to kick off in 2026.
Influenza remains a major global public health threat. According to the World Health Organization (WHO), around a billion cases of seasonal influenza are reported annually, including 3–5 million cases of severe illness.1 Vaccination stands as the most cost-effective approach to prevent the disease, which helps reduce influenza infections as well as associated complications, hospitalizations, and deaths.
To date, SINOVAC’s seasonal influenza vaccines have been widely distributed in about 20 countries and regions worldwide, with a cumulative supply exceeding 120 million doses. In December 2025, the vaccine obtained marketing approval in the United Arab Emirates (UAE). The first batch was shipped to the UAE in April, marking SINOVAC’s first delivery of influenza vaccines to Gulf Cooperation Council (GCC) member states. Additionally, SINOVAC has been the exclusive supplier for Chile’s national influenza vaccine procurement program for two consecutive seasons (2025–2026), supporting the country’s influenza prevention and control efforts.
SINOVAC continues to invest in the research and development of influenza vaccines. The company has advanced clinical development across multiple technical platforms, striving to bolster influenza prevention and control worldwide.
Reference:
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.